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Background: A malaria vaccine that targets the sporozoite/liver stage parasites could potentially prevent blood
stage infection and the associated clinical symptoms. Identification of sporozoite/liver stage antigens is, therefore,
crucial for the development of effective vaccines. Cell-traversal protein for ookinetes and sporozoites (CelTOS) is a
highly conserved antigen involved in sporozoite motility and hepatocyte invasion and has been shown to induce
significant IFN-γ production in PBMCs from radiation-attenuated sporozoite-immunized malaria-naïve individuals.
The aim of this study was to ascertain whether such CelTOS-specific recall responses are also induced in individuals
with natural exposure to Plasmodium falciparum.
Methods: Ex vivo IFN-γ responses to 15mer overlapping peptide pools covering the entire sequence of CelTOS and
five other candidate antigens, CSP, AMA1, MSP1, TRAP and LSA1, were characterized using PBMCs from 35 malaria
exposed adults. Responses to four CelTOS peptide pools (CelTp1, CelTp2, CelTp3 and CelTp4), a pool containing
peptides from the entire CelTOS antigen (CelTTp), and pools comprised of overlapping peptides from each of the
other five malaria antigens were assessed by ex vivo ELISpot assay. A positive IFN-γ response for stimulants was
defined by two criteria; a stimulation index of two or greater relative to the unstimulated control, and a difference
of 10 or greater in spot forming cells between stimulant and the unstimulated control.
Results: Of the 35 volunteers tested, five had positive IFN-γ recall responses against the four different CelTOS pools
while four volunteers made responses against the CelTTp pool; six volunteers were, therefore, positive with CelTOS.
By contrast, six volunteers responded to AMA1, seven to LSA1, 15 to MSP1 and two volunteers responded against
CSP and TRAP.
Conclusions: These results suggest natural malaria transmission induces CelTOS-specific ex vivo IFN-γ in Ghanaian
adults and that the frequency of these responses was similar to those of other previously characterized malaria
antigens. These findings support the further evaluation of CelTOS as a pre-erythrocytic candidate antigen for inclusion
in a potential multi-antigen vaccine.
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Current malaria control strategies combine identification
and elimination of vectors with prompt diagnosis and
treatment of infected individuals in endemic popula-
tions. Various insecticides have been applied for the
control of the mosquito vectors, and chemoprophylaxis
is used to prevent blood stage infection associated with
the clinical symptoms of malaria. These disease control
measures are however being hampered by the resistance
of parasites and mosquito vectors to drugs and insecti-
cides respectively [1]. Vaccines are an essential and cost-
effective public health tool and it is believed that the
development of anti-malarial vaccines would be an im-
portant addition to existing control strategies. The feasi-
bility of developing a malaria vaccine is firstly suggested
by the acquisition of partial clinical immunity following
repeated exposure to parasites during natural transmission
in malaria-endemic areas [2,3]. Secondly immunization
with radiation-attenuated sporozoites has been shown to
induce sterile protection against the sporozoite and liver
stages of the parasite [4,5].
The malaria parasite has a complex life cycle and it is
believed that an effective anti-malarial subunit vaccine
may need to target antigens in multiple stages of the
parasite. The Plasmodium falciparum cell-traversal pro-
tein for ookinetes and sporozoites (CelTOS) is required
for motility of the parasite in both the mosquito vector
and the human host, and is required for successful mal-
aria infections [6]. Anti-CelTOS antibody responses in
mice have been shown to inhibit sporozoite motility and
invasion of hepatocytes in vitro, and induced sterile pro-
tection in test animals [7,8]. Moreover, CelTOS peptides
elicited proliferative and IFN-γ responses in ex vivo
ELISpot assays using peripheral blood mononuclear cells
(PBMCs) from irradiated sporozoite-immunized volun-
teers [9]. There are, however, no reports on the induction
of naturally acquired cell-mediated immune responses to
CelTOS in populations in malaria-endemic areas.
Ex vivo ELISpot assays have previously been shown to
be capable of detecting recall IFN-γ responses from adults
in Ghana using HLA-matched DR- or class I-restricted
peptides derived from the circumsporozoite protein (CSP),
thrombospondin-related adhesion protein (TRAP), liver
stage antigen-1 (LSA1), liver stage antigen-3 (LSA3) and
exported protein-1 (EXP1) [10]. Moreover, since responses
were generally low, in the same study non-HLA matched
peptides from CSP and apical membrane antigen-1
(AMA1) were used to determine the reproducibility of
ex vivo ELISpot assays, and found that using positivity cri-
teria defined as at least a two-fold difference comparing
test samples and medium controls, and at least a differ-
ence of 10 spot forming cells (sfc) per million PBMC be-
tween test samples and medium controls, led to 60%
reproducibility [10]. The aim of this study was, therefore,to determine whether CelTOS peptides could induce
IFN-γ recall responses in PBMCs from volunteers in
Ghana using ex vivo ELISpot assays, using the positivity
criteria based on that study [10]. Pools of peptides from
CSP, TRAP, LSA1, AMA1 and merozoite surface protein-1
(MSP1) were concurrently used for PBMC stimulation. For
each of these additional antigens, a single pool of peptides
covering the entire antigen was used, rather than HLA-
matched individual peptides, with the assumption that
such pools contain multiple HLA-restricted epitopes that
match the HLA of each subject. The results showed that
with the exception of MSP1, CelTOS peptides recalled a
similar frequency of positive responses as the other four
antigens, suggesting that CelTOS may be a potentially im-




This study was conducted according to a human use
protocol “Quality Control of Immunological Reagents and
Validation of Improvements to Immunological Assays in
Support of Malaria Vaccine Trials” approved by Intuitional
Review Boards at the Noguchi Memorial Institute for
medical Research (NMIMR) and the Naval Medical
Research Center (NMRC). NMIMR holds a United States
Government Federal Wide Assurance (FWAA00001824)
from the Office for Human Research Protections, as does
NMRC (FWA00000152). NMRC also holds a Department
of Navy Addendum to the FWA for human subject protec-
tions. Written informed consent was sought from all study
participants who willingly agreed to be part of the study
and met the inclusion criteria.
Study area and sampling
The study was conducted within the University of Ghana,
Legon and its surrounding communities in Accra, Ghana.
Legon is an urban community that lies within latitude
5.65 (5° 39′ 0 N) and longitude −0.18 (0° -11' 0 W). It is
about 10 kilometres north from the capital city, Accra. It
is home to the University of Ghana, and a 10 square km
area around Legon has an approximate population of
100,000. The average annual rainfall in the study area is
below 1000 mm and more than half of this figure is
usually recorded between April and June. Malaria trans-
mission follows the pattern of rainfall and most malaria
admissions to the health facilities occur between May and
August. Malaria transmission in the study area however
occurs mainly along the peri-urban fringes that have suit-
able breeding sites for the mosquito vector. Malaria slide
positivity in the study area is usually below 1% for most of
the year [10]. Study participants were male and female
adults between 24–43 years (average age 29 years) who
were resident in the study area. Female participants were
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study participants were tested using test strip (Accurate
Pregnancy Urine Test kit, USA) for the detection of
human chorionic gonadotrophin (hCG). The level of
haemoglobin (Hb) in study participants was measured
using HemoCue (HemoCue® Hb 201 System, Sweden).
Participants with haemoglobin > 10 g/dl and whose blood
pressure fell outside the range 120-139/80-89 were ex-
cluded from the study. All participants generally had a
normal medical history at screening and physical exam-
ination. A total of 45 volunteers were screened and 35
who met the inclusion criteria were included in the
study. The 35 selected study participants were subse-
quently screened for malaria parasites by rapid diag-
nostic test (RDT) kits and by light microscopy. Sixty
millilitres (60 ml) of venous blood was collected per
participant into heparinized tubes. PBMCs were iso-
lated from blood by gradient centrifugation using Accuspin
Histopaque-1077 cell separating tubes. After washing and
counting, cells were rested in an incubator at 37°C, 5%
CO2 for a maximum of 20 h before use in ex vivo ELISpot
assays.
Synthetic peptides and peptide pools
Synthetic 15mer peptides that overlap by 11 amino acids
and span the full length CelTOS, CSP, AMA1, TRAP,
the 42 kDa fragment of MSP1 and truncated C-terminal
portion of LSA1, all 3D7 strain, were synthesized by
Mimotopes, VIC, Australia (>80% purity). CelTOS pep-
tides were grouped into four CelTOS peptide pools
(CelTp1, CelTp2, CelTp3 and CelTp4) or combined
into one pool (CelTTp) (Table 1). Similarly, overlapping
15mer peptides that represent either the full length an-
tigens (CSP, TRAP, AMA1) or partial antigen sequences
(LSA1 and MSP1) were combined into single peptide
pools per antigen, designated as CSPp, AMA1p, LSA1p,
TRAPp and MSP1p.
Ex vivo ELISpot IFN-γ Assay
ELISpot IFN-γ assays were performed as previously de-
scribed [10]. Multiscreen plates (Millipore Corporation,
USA) were coated with Monkey anti-human IFN-γ
(Mabtech AB, USA) and PBMCs (400,000 cells/well)Table 1 CelTOS peptide pools used in ELISpot assays
Peptide pool Peptide pool
name
Amino acids Number of peptides
CelTOS pool 1 CelTp1 1 - 55 11 peptides (1–11)
CelTOS pool 2 CelTp2 45 - 99 11 peptides (12 – 22)
CelTOS pool 3 CelTp3 89 - 143 11 peptides (23 – 33)
CelTOS pool 4 CelTp4 133 - 182 10 peptides (34 – 43)
CelTOS single pool CelTTp 1 - 182 43from each volunteer were tested in duplicate with 10 μg/ml
of each of the five CelTOS peptide pools (CelTp1, CelTp2,
CelTp3, CelTp4, CelTTp) or with 1.25 μg/ml of the other
single pools from CSPp, AMA1p, LSA1p, TRAPp, and
MSP1p. Concanavalin A (Con A, Sigma Aldrich, USA)
at a concentration of 0.313 μg/ml and CEF (consisting
of 32 HLA class I-restricted peptides from CMV, EBV
and Flu, Cellular Technology Ltd, USA.) at a concen-
tration of 2.0 μg/ml were used as positive control stim-
ulants and tested in triplicate with 100,000 PBMCs/well
as previous data showed that for most volunteers, testing
at 400,000 PBMCs per well gave spots that were too
numerous to count [11]. Volunteer PBMCs that were in-
cubated with medium only were used as controls and
PBMCs from malaria-naive volunteers from USA were
incubated with all test peptides and CEF for internal con-
trol purposes. After PBMC incubation for 36 hours,
spots were detected by incubation with biotinylated
anti-IFN-γ polyclonal antibody (Mabtech, USA) and
subsequently with alkaline-phosphatase-conjugated strep-
tavidin (Mabtech, USA). After plate development with
chromogenic substrate for alkaline phosphatase (Bio-Rad,
USA), the number of IFN-γ-producing spots per well was
estimated using an automated ELISpot plate reader (AID
GmbH, Germany) and the acquired data was exported into
Microsoft Excel for analysis.
Data analysis
Activities were calculated as spot forming cells per mil-
lion PBMCs (sfc/m). The assay was considered positive
if there was (1) at least a doubling of sfc/m in test wells
relative to control wells, and (2) a difference of at least
10 spots between test and control wells, based on our
previous studies [10]. A volunteer was considered posi-
tive to a malaria antigen if his/her PBMC tested positive
against at least one peptide pool. Fisher’s exact test was
used to compare proportions of IFN-γ responders be-
tween the CelTTp pool and those of the five other P. fal-
ciparum antigens (CSP, AMA1, TRAP, LSA1 and MSP1).
Subsequently a pairwise post hoc test for differences in
proportions was performed when statistically significant
differences were observed in proportions of positive re-
sponders to the various antigens. Statistical analysis and
graphics were done with Graph Pad prism (version 5.04,
San Diego, CA, USA) and the R statistical package
(version 3.0.2, R development core team). A p value less
than 0.05 was considered statistically significant.
Results
Participant flow
A total of 45 healthy Ghanaian adults were screened
and 35 volunteers who met eligibility requirements and
gave informed consent participated in the study. Volun-
teers were between 24 and 43 years with an average age
Figure 1 Magnitude of IFN- γ responses to the four separate CelTOS pools. For each volunteer, stacked bars represent responses to the five
pools and bars with asterisks (*) are responses that were positive based on the set positivity criteria. The plotted data are those over the medium
background responses (difference between activities for test peptide-stimulated PBMCs and unstimulated control PBMCs).
Figure 2 Proportion of IFN-γ positive responders to the four
separate CelTOS pools. The absolute number of responders for
each pool has been expressed as a proportion of the total number
of volunteers (35).
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pregnancy and all volunteers were negative for malaria
parasitaemia by light microscopy and malaria RDT. All
volunteers made positive IFN-γ responses to Con A or
CEF or both (Additional file 1). For each volunteer, the
ELISpot activity (sfc/m) for the unstimulated medium
control was subtracted from the activities (sfc/m) for
each test peptide. In all assays, unstimulated medium
control responses ranged between 0 and 18 sfc/m except
volunteers v15 and v28 whose mean unstimulated medium
responses were 69 and 88 sfc/m respectively.
Ex vivo ELISpot IFN-γ responses to CelTOS peptide pools
The magnitude of IFN-γ responses (sfc/m) to the
CelTOS 15mer peptide pools CelTp1, CelTp2, CelTp3
and CelTp4 is shown in Figure 1, and the proportion of
volunteers that responded to each pool is presented in
Figure 2. Overall, five of the 35 (14%) study volunteers
(v1, v4, v13, v16 and v30) were positive to at least one of
the CelTOS peptide pools. Volunteer v28 had high activ-
ities in both test and control wells and was therefore not
considered positive. Four of the five positive volunteers
had positive activities to CelTp1 (v1, v4, v13 and v30),
two of these were also positive with CelTp2 (v1 and v16)
and one (v1) was positive with CelTp3. No activity was
detected to CelTp4. The highest response was that of
volunteer v1 to CelTp3 (64 sfc/m) and this volunteer also
had the most positive responses (against CelTp1, CelTp2
and CelTp3, Figure 1). The remaining 30 volunteers didnot respond to any of the CelTOS peptide pools, al-
though they responded positively to Con A and CEF,
except for v26 who responded only to CEF (Additional
file 1). PBMCs from two malaria-naïve donors that were
repeatedly stimulated with the same parasite peptides
pools did not make any antigen-specific responses, though
these cells also responded to stimulation with CEF controls
(Additional file 2).
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TRAPp and MSP1p pools
IFN-γ responses to peptide pools representing the six
tested malaria antigens CelTOS, CSP, AMA1, LSA1,
TRAP and MSP1 are shown in Figure 3. Responses dif-
fered among volunteers, probably due to their different
HLA molecules. However, 17 of the 35 volunteers (49%)
responded to at least one of the tested malaria antigen
peptide pools. The frequency of positive volunteers to each
antigen is shown in Figure 4. The most frequent positive
response was to MSP1p (15/35 volunteers, 43%), fol-
lowed by LSA1p (7/35, 20%), AMA1p (6/35, 17%), CelTTp
(4/35, 11%), CSPp (2/35, 6%) and TRAPp (2/35, 6%). Three
of the five volunteers that were positive against at least one
of the four separate CelTOS pools (CelTp1, CelTp2,
CelTp3 and CelTp4) were also positive against CelTTp
(v1, v4, and v16), and in addition one volunteer (v32) who
was negative against all four separate CelTOS pools was
positive against CelTTp. Overall, among the 35 volunteers,
four/35 (11%) were positive against one antigen (only
MSP1p), 13/35 (29%) were positive against at least two dif-
ferent antigens, five/35 (14%) were positive against at least
three antigens, and only v16 (3%) was positive against four
antigens. Six of thirty five (6/35) volunteers (17%) had
summed activities greater than 100 sfc/m, and LSA1p
and/or MSP1p made the greatest contributions; TRAPp
made the greatest contributions to the next two highest vol-
unteers (6%). Eighteen volunteers (51%) did not respond to
any of the malaria antigen pools although they responded
to stimulation with Con A and CEF (Additional file 1).Figure 3 Magnitude of IFN- γ responses to CelTTp and the five other
responses to the six single pools and bars with asterisks (*) are positive res
medium background responses (difference between activities for test peptComparison of CelTOS peptide pool responses to those
of other anti-malarial antigen pools
Comparison of responder frequencies to peptide pools
from the six malaria antigens tested showed statistical
significance in differences between at least two of the six
peptide pool responses (p = 0.0006, Fisher’s Exact test).
Post-Hoc pairwise comparison revealed that the propor-
tion of positive responses against CelTTp was not sig-
nificantly different from that against any of the other
five antigen pools (p > 0.05 in all cases, pairwise propor-
tion tests with Holm’s correction, Table 2). The propor-
tion of positive responses against MSP1p was however
significantly higher than those against TRAPp and CSPp
(p = 0.012 in both cases, Table 2). Comparison of the
median activities (sfc/m) to each peptide pool for the 35
volunteers showed that there were no statistically sig-
nificant differences in activities amongst the antigens
(p = 0.27, Kruskal-Wallis test). Therefore, the proportion of
positive volunteers and the magnitude of responses to
CelTTp were similar to those observed for the malaria vac-
cine candidates CSP, TRAP, LSA1, and AMA1 and MSP1.
Discussion
The development of an effective anti-malarial vaccine is
an important public health priority as it will add to the
currently available disease control tools. Subunit vaccine
development requires the identification of conserved
immunodominant antigens from multiple stages of the
parasite in order to ensure broad protection and curtail
disease transmission. CelTOS is a pre-erythrocytic malariamalarial antigens. For each volunteer, stacked bars represent
ponses as defined in the Methods. The plotted data are those over the
ide-stimulated PBMCs and unstimulated control PBMCs).
Figure 4 Proportion of IFN-γ positive responders to the six malaria vaccine candidate antigens. The absolute number of responders for
each pool has been expressed as a proportion of the total number of volunteers (35). *Proportions that were positive against CSPp and TRAPp
were significantly different from that of MSP1p in pairwise comparisons.
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potent antibody and T cell responses and prevent the es-
tablishment of blood stage infection in mice [6-8]. CelTOS
15mer peptides also elicited HLA-restricted IFN-γ re-
sponses in ex vivo ELISpot assays using PBMC from irra-
diated sporozoite-immunized volunteers [9]. Moreover,
CelTOS is a relatively conserved antigen and elicits cross-
protective immune responses against heterologous chal-
lenge with Plasmodium berghei [6,7]. CelTOS based
vaccines have been shown to elicit both antibody and T
cell responses in experimental animal models [7,8,12,13],
and phase 1 clinical trials of a CelTOS vaccine known as
FMP012 in malaria-naïve volunteers has just been com-
pleted (https://clinicaltrials.gov/ct2/show/NCT01540474).
However, very little is known about naturally induced im-
mune responses to CelTOS in a population with exposure
to P. falciparum. A previous study with volunteers agedTable 2 P values for pairwise comparison of responder
proportions amongst single antigen pools
AMA1p CelTTp CSPp LSA1p MSP1p
CelTTp 1.000 - - - -
CSPp 1.000 1.000 - - -
LSA1p 1.000 1.000 1.000 - -
MSP1p 0.443 0.094 0.012 0.787 -
TRAPp 1.000 1.000 1.000 1.000 0.012
Pairwise comparison of responder frequencies to all antigens was performed
with Holm’s correction. Prior to performing the pairwise test, Fisher’s Exact test
for multiple comparison of proportions of positive volunteers to the six peptide
pools showed that the proportion of positive responders was significantly
different between at least two pairs of antigens (p < 0.05). Proportions of
positive responders for antigen pools are shown in Figure 4.one to 30 years and living in a low malaria transmission
area of southern Ghana showed very low levels of natur-
ally induced CelTOS-specific antibodies [14]. The aim of
the current study was to investigate the induction of
CelTOS-specific IFN-γ recall responses in PBMCs from
Ghanaian adult volunteers in an area (Legon) with natural
exposure to P. falciparum parasites, which was previously
confirmed by seropositivity to erythrocytic stage antigens
[10]. However, in that previous study, only a proportion of
subjects had recall ELISpot activities to six malaria anti-
gens that were tested, suggesting that cellular responses
may be shorter-lived than antibody responses [10].
Four pools of 15mer peptides that together span the
entire amino acid sequence of CelTOS were tested against
PBMCs from 35 study volunteers. Fourteen percent (14%)
of volunteers made positive responses to the four CelTOS
peptide pools, and all positive responses were to the first
three peptide pools (CelTp1, CelTp2 and CelTp3) with no
response to CelTp4 (Figures 1 and 2). By contrast, 49% of
volunteers made positive responses to one or more of the
six single peptide pools spanning the full length antigens
(CelTTp, AMA1p, CSPp and TRAPp) or partial sequences
(LSA1p and MSP1p), shown in Figures 3 and 4. Since one
volunteer who was negative with the individual CelTOS
pools, was positive to the single CelTTp pool, six/35 (17%)
of volunteers were positive to CelTOS. This was not re-
lated to the viability of the PBMC, as all volunteers made
positive responses to the Con A and CEF (Additional
file 1), with the exception of volunteers v13, v16 and v26
whose cells at 100,000/well did not make responses to
Con A, suggesting that PBMCs used for IFN-γ response
assessment were viable. The magnitude of responses to
Anum et al. Malaria Journal  (2015) 14:20 Page 7 of 8CEF peptides in this study (Additional file 1) was gener-
ally similar to those in a previous study with volunteers
from the same study area [10]. The mean CEF response
in PBMCs from the 29 volunteers with positive IFN-γ
responses (1032 sfc/m) was however up to five times
higher than the average response (216 sfc//m) mea-
sured in PBMCs from the two malaria-naïve volunteers
(Additional file 2). In addition, anti-CelTOS IFN-γ re-
sponses observed in this study were several orders
lower than the average response observed in a previous
study with PBMCs from attenuated sporozoite-immunized
volunteers [9].
These results show that peptide pools from the N-
terminal end of CelTOS (CelTp1, CelTp2, CelTp3) in-
duced responses whereas the C-terminal peptide pool
(CelTp4) did not (Figure 1). This suggests a greater
prevalence of T cell epitopes in the N-terminal region of
CelTOS. Preliminary predictions using the bioinfor-
matic algorithm NetMHC [15] identified more Class
1-restricted epitopes within CelTp1, CelTp2 and CelTp3
than CelTp4 [9]. This is in agreement with the ex vivo
ELISpot results presented here and suggest that at least
some of the responses observed in the current study are
likely to be CD8+ T cell-specific. Despite the conserved
nature of the celtos gene, a limited number of single nu-
cleotide polymorphisms (SNPs) have been mapped to the
C-terminal region of the protein sequence that has been
predicted to have immunodominant B cell epitopes [16]
and may thus be more involved in immune escape against
CelTOS-specific antibody responses. Ex vivo ELISpot
analysis of mouse PBMCs showed a concentration of
immunogenic T cell epitopes at the C terminal end of
CelTOS, although murine HLA-restricted CD4+ and
CD8+ epitopes were predicted by bioinformatics tools to
be distributed over the entire antigen in the same study
[17]. It is possible that differences between murine and
human HLA-restricted CelTOS epitopes may explain dif-
ferences in ELISpot data between that study and the
current study. However, on the basis of data from this and
other human studies [9], there is likely to be little effect of
the limited polymorphism in CelTOS on anti-CelTOS T
cell IFN-γ responses. Elucidation of the HLA restriction of
observed responses by CD4+/CD8+ cell depletion ELISpot
assays or by flow cytometric analysis and HLA-specific
peptides will help determine the T cell subset specificity
of observed responses and further establish the use of
CelTOS as a malaria vaccine in genetically-diverse popula-
tions especially in Africa [18].
In these studies the proportion of positive volunteers
was greatest to the blood stage antigen MSP1 but statis-
tically, only the difference between responders to MSP1
on the one hand and CSP and TRAP on the other
hand was significant (Figure 4, Table 2). The propor-
tions of positive volunteers to the other antigens werestatistically similar. The overall magnitudes of responses
were similar against all antigens tested; however, indi-
vidual responses were highest against MSP1, LSA1 and
TRAP in eight volunteers (Figure 3). These observa-
tions may be partially explained by the fact that blood
stages persist for longer during malaria infection and
thus induce responses in a greater proportion of volun-
teers (MSP1), while LSA1 contains more immunogenic
epitopes than other malaria antigens [19]. A number of
studies in both naturally exposed individuals and naïve
volunteers immunized with radiation-attenuated sporo-
zoites have found numerous CD4+ and CD8+ T cell
epitopes in MSP1, with most of these being limited es-
pecially to the 42 kDa fragment of protein [20-22]. How-
ever, the involvement of CD4+ or CD8+ T cells in these
ELISpot activities was not determined in the current
study.
In a previous study, short Class I-restricted and DR-
restricted long peptides representing CSP, TRAP, and
LSA1 were used as stimulants and these matched the
HLA of volunteers in Ghana [10]; in total 12/26 volun-
teers (46%) were positive, comparable with the total
number 17/35 volunteers (49%) who were positive against
CSP, TRAP and LSA1, in addition to AMA1 and MSP1 in
this study (Figure 3). Thus pools of peptides spanning the
entire length of malaria antigens were as effective in elicit-
ing ex vivo IFN-γ responses as HLA-matched single pep-
tides. In that earlier study the highest frequency of
responses was to LSA1 [10] and MSP1 was not tested in
that earlier study.
In summary, CelTOS-specific T cell responses were
detected in five out of 35 study volunteers who have a
history of exposure to P. falciparum. The proportion of
volunteers who responded to the CelTOS antigen was
not significantly different from the proportions that
responded to other established malaria vaccine candidate
antigens. Immune responses to CelTOS may block the
development of pre-erythrocytic parasites and have the
potential to protect malaria endemic populations by
reducing or preventing infection of liver cells by sporo-
zoites, thereby reducing disease severity. Since natural
transmission and immunization with irradiated sporozo-
ites induce cellular IFN-γ responses to CelTOS, these
findings support further evaluation of CelTOS as a pre-
erythrocytic candidate antigen for inclusion in a poten-
tial multi-antigen vaccine. It has been shown previously
that two vaccine candidate antigens, CSP and AMA1,
combined in a DNA-prime, adenovirus-boost vaccine
regimen induced complete protection that was primarily
mediated by CD8+ T cell IFN-γ responses in 4/15 volun-
teers to malaria challenge [23,24]. It is possible that
inclusion of other antigens such as CelTOS that also in-
duce cellular IFN-γ responses may increase efficacy of
this vaccine.
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Natural malaria transmission in an endemic area in
Ghana induces cellular IFN-γ responses against CelTOS
in adults that were similar to responses against other
pre-erythrocytic antigens CSP, TRAP and LSA1. These
results support further development of CelTOS as a
malaria vaccine, either alone or in combination with
other antigens.
Additional files
Additional file 1: IFN-γ responses to Con A and CEF in PBMCs from
the 35 volunteers. One hundred thousand (100,000) PBMCs were
stimulated in triplicate with both Con A and the CEF peptide pool and
the resulting number of spots averaged and expressed as sfc/m PBMCs.
The data plotted are responses over the medium background responses.
Volunteers v1, v6, v18, v19, v23 and v33 were positive to Con A but not
to CEF while v13, v16 and v26 were positive to CEF but not to Con A,
based on the set positivity criteria. Responses by all other volunteers
were positive to both Con A and CEF.
Additional file 2: IFN-γ responses to all test peptides and CEF in
PBMCs from two malaria-naïve volunteers. Test peptides were used
to stimulate 400,000 PBMCs/well and CEF was used to stimulate 100,000
PBMCs/well of malaria-naïve volunteer PBMCs before expression as sfc/m
PBMCs. Responses in both volunteers were negative to all test peptides
and positive to the CEF peptide pool.
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